ARHGAP6

Across TCGA pan-cancer cohorts, ARHGAP6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGAP6 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARHGAP6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where ARHGAP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.894	0.572	<.001	88	view →
CCRCC	DFS	Tertile	All	0.895	0.666	.012	19	view →
UCEC	OS	Quartile	III,IV	0.258	1.000	.018	12	view →
LUAD	DFS	Median	II,III,IV	0.691	0.950	.001	10	view →
LSCC	DFS	Quartile	II,III,IV	0.549	0.927	.025	4	view →
HNSC	OS	Tertile	III,IV	0.779	0.570	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGAP6–PDAC (DFS)

Open the PDAC breakdown →